Dyne Therapeutics, Inc. (DYN)
Data as of , from SEC Form 4 filings.
See up to 3 months of DYN. The 7-day demo opens the 1M and 3M ranges and puts DYN on your watchlist.
Start 7-day demoLatest DYN insider trades
About Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- WALTHAM, MA
- 258
- 2020
- XNAS
DYN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 2,500 | $40K |
| Open-market sale | 17 | 2,868,731 | $72.33M |
DYN insider transactions (Form 4)
6487 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Brian S. Posner - Director | Open-market purchase | Common Stock | 2,500 | $16.00 | $40K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 900 | $24.35 footnote F2 | $22K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 185 | $18.88 footnote F4 | $3K | |
| ||||||
| Douglas Kerr - Officer | Open-market sale | Common Stock | 3,745 | $24.35 footnote F2 | $91K | |
| Douglas Kerr - Officer | Open-market sale | Common Stock | 1,290 | $18.88 footnote F4 | $24K | |
| ||||||
| Open-market sale | Common Stock | 5,658 | $18.88 footnote F2 | $107K | ||
| ||||||
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 268,354 | $26.20 footnote F2 | $7.03M | |
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 94,415 | $26.20 footnote F2 | $2.47M | |
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 63,643 | $26.20 footnote F2 | $1.67M | |
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 1,359,674 | $25.00 footnote F6 | $33.99M | |
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 478,377 | $25.00 footnote F6 | $11.96M | |
| Jason P. Rhodes - Director | Open-market sale | Common Stock | 322,465 | $25.00 footnote F6 | $8.06M | |
| ||||||
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 226 | $26.28 footnote F2 | $6K | |
| ||||||
| Douglas Kerr - Officer | Open-market sale | Common Stock | 1,556 | $26.28 footnote F2 | $41K | |
| ||||||
| Open-market sale | Common Stock | 4,986 | $26.28 footnote F2 | $131K | ||
| ||||||
| Erick Lucera - Officer | Open-market sale | Common Stock | 1,797 | $26.28 footnote F2 | $47K | |
| ||||||
| Dirk Kersten - Director | Open-market sale | Common Stock | 256,072 | $25.50 footnote F2 | $6.53M | |
| Dirk Kersten - Director | Open-market sale | Common Stock | 5,388 | $26.04 footnote F5 | $140K | |
| ||||||
| Jason P. Rhodes | Open-market sale | Common Stock | 253,039 | $22.79 footnote F2 | $5.77M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 127,182 | $22.79 footnote F2 | $2.90M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 100,019 | $22.79 footnote F2 | $2.28M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 124,379 | $23.17 footnote F6 | $2.88M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 29,587 | $23.62 footnote F7 | $699K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 62,543 | $23.17 footnote F6 | $1.45M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 14,844 | $23.62 footnote F7 | $351K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 49,193 | $23.17 footnote F6 | $1.14M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 11,665 | $23.62 footnote F7 | $276K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 5,000 | $23.61 footnote F8 | $118K | |
| ||||||
| Jason P. Rhodes | Open-market sale | Common Stock | 81,903 | $21.28 footnote F2 | $1.74M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 64,411 | $21.28 footnote F2 | $1.37M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 102,969 | $21.14 footnote F6 | $2.18M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 51,756 | $21.14 footnote F6 | $1.09M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 40,702 | $21.14 footnote F6 | $860K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 162,954 | $21.28 footnote F2 | $3.47M | |
| ||||||
| Erick Lucera - Officer | Open-market sale | Common Stock | 2,362 | $20.37 footnote F2 | $48K | |
| ||||||
| Jason P. Rhodes | Open-market sale | Common Stock | 12,699 | $21.10 footnote F7 | $268K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 6,382 | $21.10 footnote F7 | $135K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 5,019 | $21.10 footnote F7 | $106K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 77,855 | $21.13 footnote F2 | $1.65M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 39,131 | $21.13 footnote F2 | $827K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 30,774 | $21.13 footnote F2 | $650K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 50,530 | $21.02 footnote F6 | $1.06M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 25,397 | $21.02 footnote F6 | $534K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 19,973 | $21.02 footnote F6 | $420K | |
| ||||||
| Dirk Kersten | Open-market sale | Common Stock | 1,657 | $21.47 footnote F6 | $36K | |
| Dirk Kersten | Open-market sale | Common Stock | 190,676 | $20.57 footnote F2 | $3.92M | |
| Dirk Kersten | Open-market sale | Common Stock | 71,629 | $21.04 footnote F5 | $1.51M | |
| ||||||
| Barry E. Greene | Grant or award | Stock option (right to buy) | 57,463 | $0.00 | - | |
| Dirk Kersten | Open-market sale | Common Stock | 37,454 | $20.14 footnote F2 | $754K | |
| Dirk Kersten | Open-market sale | Common Stock | 46,901 | $20.07 footnote F5 | $941K | |
| ||||||
| Douglas Kerr - Officer | Open-market sale | Common Stock | 887 | $18.33 footnote F2 | $16K | |
| ||||||
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 145 | $18.33 footnote F2 | $3K | |
| ||||||
| Open-market sale | Common Stock | 2,683 | $18.33 footnote F2 | $49K | ||
| ||||||
| Edward Hurwitz | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| David Charles Lubner | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Jason P. Rhodes | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Dirk Kersten | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Carlo Incerti | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Catherine Stehman-Breen | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,000 | $16.94 | $34K | |
| Brian S. Posner | Grant or award | Stock option (right to buy) | 35,152 | $0.00 | - | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,500 | $17.48 | $44K | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,000 | $18.21 | $36K | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,500 | $17.12 | $43K | |
Recent DYN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Kerr Douglas | Officer | 35 | $661 | View on EDGAR | |
| Cox John | Officer | 5,658 | $107K |
DYN insider trading FAQ
What is the latest insider trade for DYN?
Dyne Therapeutics, Inc. (DYN) had 10 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for DYN runs to 87 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DYN stock?
1 insider purchase of DYN was filed in the last 90 days, totaling $40K.
How many insiders are selling DYN stock?
17 insider sales of DYN were filed in the last 90 days, totaling $72.33M.
Where can I see DYN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DYN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Brian S. Posner view on EDGAR
- - Johanna Friedl-Naderer view on EDGAR
- - Douglas Kerr view on EDGAR
- - John Cox view on EDGAR
- - Jason P. Rhodes view on EDGAR
- - Johanna Friedl-Naderer view on EDGAR
- - Douglas Kerr view on EDGAR
- - John Cox view on EDGAR
- - Erick Lucera view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where DYN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DYN with a 7-day demo
- DYN on your watchlist
- Every DYN Form 4 filing on record
- Up to 3 months of DYN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive